Status:
COMPLETED
Interleukin 33 in Juvenile Idiopathic Arthritis Patients
Lead Sponsor:
Benha University
Conditions:
Juvenile Idiopathic Arthritis
Eligibility:
All Genders
Up to 16 years
Brief Summary
The aim of this study is to measure serum and synovial fluid levels of IL 33 and its relative mRNA expression in peripheral blood mononuclear cells in juvenile idiopathic arthritis (JIA) patients and ...
Detailed Description
SUBJECTS AND METHODS Subjects:This study will be a case-control study including sixty children with juvenile idiopathic arthritis attending pediatric rheumatology clinic of Benha University Hospital ...
Eligibility Criteria
Inclusion
- Children less than 16 years old diagnosed according to ILAR classification criteria of juvenile idiopathic arthritis
Exclusion
- 1-Exclusion other causes of arthritis in children as:
- Other autoimmune diseases Vasculitis- SLE- Rheumatic fever- Dermatomyositis- Polymyositis- Enteropathic arthritis- Behcet disease- Sjogren-Scleroderma- Mixed connective diseases
- Infectious disease or septic arthritis.
- Metabolic diseases.
- Endocrine diseases.
- Neuropathic diseases.
- Heritable bone disease.
- Neoplastic diseases including leukemia.
- Sarcoidosis.
- Familial Mediterranean fever. 2-Exclusion of children with diseases that affect serum level of IL 33 as:
- <!-- -->
- Inflammatory diseases of airway e.g asthma
- Inflammatory bowel disease
- Systemic lupus erythmatosus
- Inflammatory skin disease e.g :atopic dermatitis
- Cancer
Key Trial Info
Start Date :
February 12 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 20 2019
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT03835624
Start Date
February 12 2019
End Date
November 20 2019
Last Update
December 11 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Benha University Hospital
Banhā, Qalyubia Governorate, Egypt, 13518